{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025712","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.891507+00:00","generated_at":"2026-06-21T12:47:51.683759+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus reports positive Phase 2 interim results for domvanalimab combo in NSCLC","bullets":["Fourth interim analysis of ARC-7 trial (n=133) shows domvanalimab-containing arms differentiate from zimberelimab monotherapy.","Clinically meaningful improvements in objective response rate, PFS, and six-month landmark PFS observed.","No unexpected safety signals; domvanalimab arms generally well tolerated with safety consistent with individual molecules.","Detailed results to be presented at ASCO Monthly Plenary Series on December 20, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025712","json":"https://secwatch.observer/filing/0000950170-22-025712.json","markdown":"https://secwatch.observer/filing/0000950170-22-025712.md","text":"https://secwatch.observer/filing/0000950170-22-025712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/0000950170-22-025712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022025712/rcus-20221128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:47:51.683759+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}